Blue Jet Healthcare Limited — Q1 FY26 earnings call

Call held 22 Jul 2025

Management summary

Blue Jet Healthcare reported a strong Q1 FY26 with revenue up 118% YoY to ₹354.8 crores and PAT up 114% YoY to ₹91.2 crores. Despite a QoQ decline in EBITDA and gross margins due to inventory adjustments and product mix, management expressed confidence in sustaining growth and margins for FY26, driven by capacity expansions and a robust CDMO pipeline. The company is advancing significant capex for new facilities and R&D, aiming to add 1,000 KL capacity in the next 2-3 years.

Highlights

  • Revenue from operations of ₹354.8 crores, up 118% year-on-year, driven by consistent volume growth across PI, API, and contrast media platforms.

  • EBITDA grew by 178% year-on-year to ₹121 crores, reflecting strong base volume expansion and enhanced operational scale.

  • PAT increased by 114% year-on-year to ₹91.2 crores, demonstrating sustained operating leverage.

  • Healthy operating cash flows with disciplined capital deployment across R&D and capacity expansion.

  • Strong customer demand visibility and expanding product pipelines across all segments.

Concerns

  • EBITDA margin at 34% was lower quarter-on-quarter due to phasing of production, inventory normalization, and product mix.

  • Gross margin fell 6.5% QoQ to 48.5%, primarily due to a ₹75 crore drawdown in finished goods and WIP inventory, releasing absorbed overheads into the P&L.

  • A ₹2.7 crore (27 million) GST demand impacted EBITDA by approximately 0.7% as a one-time effect.

  • Forex gains were lower in Q1 due to US dollar depreciation.

Key financials

  1. Revenue from Operations 3,548 Mn +118%YoY
  2. EBITDA 1,210 Mn +178%YoY
  3. EBITDA Margin 34%
  4. PAT 912 Mn +114%YoY
  5. Net Margin 25.7%
  6. Gross Margin 48.5% -6.5%QoQ

What they filed

Q1 FY27: revenue down 17.5%, net profit down 14.3% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue208 318 340 355 165 −21%192 −40%235 −31%293 −17%
EBITDA69 124 140 121 55 −20%47 −62%71 −49%98 −19%
Net profit58 99 110 91 52 −10%40 −60%64 −42%78 −14%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • Pharma Intermediates and API
    0.082 decimal fraction QoQ Growth
  • Artificial Sweetener
    0.174 decimal fraction QoQ Growth
  • Contrast Media
    -0.039 decimal fraction QoQ Growth

Capital allocation

high confidence
  • Capex ₹280 Mn
    • Unit-3 Mahad capacity for backward integration (CMI segment) ₹3,000 Mn
    • R&D center ₹400 Mn
    • Multipurpose plant at Mahad
    In terms of CAPEX, during Q1, we approximately incurred an expenditure of 280 million. ...the earlier planned CAPEX of Rs. 250 crores for Unit-3 shall increase to about Rs. 300 crores. Of this, about Rs. 100 crores has already been incurred, and the balance Rs. 200 crores will be incurred up to FY27. The state-of-the-art R&D center being built at a cost of about Rs. 40 crores...
  • Liquidity Cash ₹2,700 Mn Company holds 2.7 billion in cash and treasury instruments and continues to generate positive operating cash flows.
    From a balance sheet perspective, we hold 2.7 billion in cash and treasury instrument and we continue to generate positive operating cash flows aligned with internal expectations.

Guidance & targets

Profitability

  • EBITDA Margin Profitability · FY26 · High confidence 34%
    EBITDA came in at Rs. 1,210 million, translating to a margin of 34%, lower quarter-on-quarter due to phasing of production, inventory normalization and product mix.

    — Shiven Arora

  • Gross Margin Profitability · coming quarters · High confidence 53%
    So, based on the current portfolio mix, it's going to be 53 and we will be in a position to sustain similar levels in the coming quarters.

    — Ganesh Karuppannan

Growth

  • Overall Business Growth Growth · FY26 · High confidence strong growth and margin trajectory
    We expect the business to maintain strong growth and margin trajectory through FY'26, and we remain focused on discipline execution, innovation-led partnerships, and long-term value creation.

    — Shiven Arora

Capacity

  • Unit-3 Mahad Commissioning Capacity · H2 FY26 · High confidence on schedule for H2 FY'26 commissioning
    Progress continues at Unit-3 Mahad, where the construction is on schedule for H2 FY'26 commissioning.

    — Shiven Arora

  • Multipurpose Plant & R&D Center Go-Live Capacity · H2 FY27 · High confidence go on stream in H2 FY'27
    At Mahad, both in the block meant for vertical integration and the multipurpose block we believe which will go on stream in H2 FY'27...

    — VK Singh

  • Additional Manufacturing Capacity Capacity · next two to three years · High confidence 1,000 KL
    In the next two to three years, maintaining the same growth momentum, we plan to add another 1,000 KL capacity...

    — VK Singh

Capex

  • Unit-3 Mahad CAPEX Capex · up to FY27 · High confidence Rs. 300 crores

    Previously Rs. 250 crores → Rs. 300 crores

    the earlier planned CAPEX of Rs. 250 crores for Unit-3 shall increase to about Rs. 300 crores. Of this, about Rs. 100 crores has already been incurred, and the balance Rs. 200 crores will be incurred up to FY27.

    — VK Singh

  • R&D Center Cost Capex · High confidence Rs. 40 crores
    The state-of-the-art R&D center being built at a cost of about Rs. 40 crores...

    — VK Singh

Efficiency

  • Asset Turn Efficiency · next five years · Medium confidence 2.5 to 3
    Our assessment over a period of, if you take the next five years, our asset turn should be somewhere close to 2.5 to 3.

    — Ganesh Karuppannan

What to watch in Q2 FY26

Gross Margin Recovery

next quarter
Current 48.5%
Target 53%

Why it matters

To confirm that the Q1 gross margin dip was indeed an aberration due to inventory adjustments and that the sustainable level of 53% is achieved.

So, based on the current portfolio mix, it's going to be 53 and we will be in a position to sustain similar levels in the coming quarters.

Risks & concerns

  • EBITDA Margin Compression

    medium

    EBITDA margin lower QoQ due to phasing of production, inventory normalization, and product mix.

    Management acknowledged

  • Gross Margin Decline due to Inventory Adjustment

    medium

    Gross margin fell 6.5% QoQ due to a ₹75 crore drawdown in finished goods and WIP inventory, releasing absorbed overheads.

    Management acknowledged

  • One-time GST Demand

    low

    A ₹2.7 crore GST demand impacted EBITDA by approximately 0.7%.

    Management acknowledged

  • Lower Forex Gains

    low

    Forex gains were lower in Q1 due to US dollar depreciation.

    Management acknowledged

  • Competition in PI Segment

    low

    Analyst questioned potential growth tapering due to rising competition, but management highlighted strong demand and lifecycle management.

    Analyst downplayed

Q&A highlights

6 direct
Gross Margin Decline and Future Outlook Direct
See, if I look at this change in the finished goods, we are actually back to the 53 levels. So, like this is just an issue which is relevant only for this. On a regular basis, we don't see any change in the gross margin with this current product.

Clarifies that the gross margin dip was due to inventory adjustment, not a fundamental shift, and management expects 53% to be sustainable.

Asked by Kunal Dhamesha

Impact of Inventory Drawdown on Gross Margin Direct
See, whenever you have a change in finished goods, whatever overhead which gets inventorized gets released to the P&L. For example, if you draw from your finished goods, whatever overhead that has been inventorized gets released to the P&L. So, there is no breakup for 4.4. It is totally the overheads, what got inventorized in the last quarter, because this time our closing finished goods is much lower compared to the previous quarter.

Explains the accounting mechanism behind the gross margin compression, attributing it to the release of previously inventoried overheads due to inventory drawdown.

Asked by Meet Katrodiya

Growth Prospects for Pharma Intermediates (PI) Segment Partial
Once again, we would reiterate that we don't really give guidance like this. But then you should not assume a quarterly run rate, right? Perhaps you have to look at larger time segment. In the CDMO business, quarter is not a very good indication. That's number one. Number two, as far as the end molecule is concerned, the growth numbers are very encouraging.

Management avoids specific quarterly guidance but indicates strong underlying demand and positive lifecycle management for the end molecule, suggesting continued growth for PI.

Asked by Meet Katrodiya

Most Bullish Business Segment Direct
So, for us, contrast media is our flagship vertical and the mainstay of the business. We are very predominantly contrast media focused company. On the other side, the PI business you have seen has gained great traction. There the addressable market is much larger, much, much larger, right? Much bigger than contrast media. So, because of the China plus one tailwinds or whatever you say, there's a lot of RFPs that we are getting over there. And then we have been, so well positioned in the sweetener business.

Management highlights all three segments (contrast media, PI, sweeteners) as having strong growth potential, with PI benefiting from a larger market and China+1 tailwinds.

Asked by Piyush Kumar

Rationale for Returning Land Parcel Direct
Actually, our application has been for a much, much larger parcel. But today in the red category, Gujarat does not have too much of land. So, we got about 8 acres. We took that, but then we felt that that was subscale because now we have spotted and in the process of finalizing a much, much larger piece of land. Therefore, it was logical for us to surrender this in view of the much larger parcel of land that we would be acquiring very shortly.

Reveals a strategic decision to acquire a significantly larger land parcel for future expansion, indicating more ambitious growth plans.

Asked by Arpit Tapadia

Capex for Pharma Intermediates and API (PI) Segment Direct
I think maybe the voice drained off and maybe you were not able to hear. Pharma intermediates is becoming an important part of the entire scheme of the company. There is one block that will come up in Mahad, which we very clearly mentioned, that's like a multipurpose block, will be catering to this segment. And even for our new big land parcel that we spoke about, our expansion plan for the future, there also we mentioned that there's going to be a multipurpose block which will be catering to this third product vertical.

Clarifies that future capex, including the multipurpose block at Mahad, is designed to support the growing PI segment, addressing analyst's concern about lack of specific PI capex.

Asked by Ayush Agarwal

Fund-raise Plans Partial
We are still in the drawing room stage. We are yet to finalize anything. As and when we conclude on this, we will actually communicate. Right now, we have just taken a shareholder resolution and we are still evaluating the options.

Indicates that the company is actively considering fundraising options, which could support its ambitious expansion plans.

Asked by Ajay

CDMO Pipeline and Peptide Segment Focus Direct
So, basically, we are working on the amino acid derivatives and peptide fragments. Till the time we build our multipurpose plant in Mahad, the smaller requirements that will be there in this segment will be catered to from the multipurpose plant in Unit 2. When the Mahad capacity comes in, that will address this business segment and demand.

Provides details on the company's strategic focus on amino acid derivatives and peptide fragments within CDMO, outlining how new capacities will support this growth area.

Asked by Kunal Dhamesha

2 min read 5 chapters

Detailed narrative

Q1 FY26 Financial Performance Overview

Blue Jet Healthcare commenced FY26 on a strong note, reporting revenue from operations of ₹354.8 crores, marking a 118% year-on-year and 4% sequential growth. This performance was driven by consistent volume growth across its Pharma Intermediates (PI), API, and contrast media segments. EBITDA for the quarter stood at ₹121 crores, translating to a 34% margin, which, while lower sequentially, represented a robust 178% year-on-year increase. Profit After Tax (PAT) was ₹91.2 crores, up 114% year-on-year, with a net margin of 25.7%.

Gross Margin Dynamics and Inventory Impact

The company's gross margin for Q1 FY26 was 48.5%, a 6.5% decline from 55% in Q4 FY25. This reduction was primarily attributed to a ₹75 crore drawdown in finished goods and Work-in-Progress (WIP) inventory, which resulted in the release of previously absorbed overheads into the P&L. Management clarified that this was an accounting effect rather than a fundamental shift in pricing or raw material costs, stating that the cumulative gross margin for Q4 FY25 and Q1 FY26 would be around 53%, which they expect to sustain in coming quarters.

Business Segment Performance and Outlook

The PI and API segment maintained strong momentum, growing 8.2% quarter-on-quarter, with expectations of additional launches in H2 FY26. The artificial sweetener segment grew 17.4% QoQ, with ASPs stabilizing after a soft FY25. Contrast media experienced a 3.9% QoQ dip due to phasing, but commercial volumes from new molecules launched in Q4 FY25 have stabilized, and sequential growth is anticipated in H2 as client offtake ramps up. Management views contrast media as its flagship vertical, while PI offers a larger addressable market with significant RFP traction.

Capacity Expansion and R&D Initiatives

Blue Jet Healthcare completed Phase 2 expansion at Unit 2, which is now fully operational. Construction at Unit-3 Mahad, intended for backward integration in the CMI segment, is on schedule for commissioning in H2 FY26. The CAPEX for Unit-3 has been revised upwards from ₹250 crores to ₹300 crores, with ₹100 crores already incurred and the balance ₹200 crores planned until FY27. A new R&D center, costing ₹40 crores, is being built to focus on peptides, GLP-1 intermediates, and biocatalysis. The company plans to add another 1,000 KL capacity over the next 2-3 years, supported by the acquisition of a larger land parcel.

CDMO Pipeline and Peptide Segment Focus

The company is actively building its CDMO pipeline, currently tracking about 20 new opportunities, with approximately six (30%) in late Phase III or commercial phase. In the peptide segment, Blue Jet Healthcare is focusing on amino acid derivatives and peptide fragments, having already developed about 45 fragments. The new multipurpose plant at Mahad and the R&D center are designed to cater to these advanced chemistry platforms, driven by client interest and a strategy to avoid the generic space.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls